Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 94 entries
View as:

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

Phase: N/A Priority: Normal
NCT ID: NCT01565707 Org: User:
Start: 06/07/12 End: 01/02/14 Due: 01/02/15

Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis

Phase: N/A Priority: Normal
NCT ID: NCT02278341 Org: User:
Start: 11/21/14 End: 07/06/18 Due: 07/06/19

A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males

Phase: N/A Priority: Normal
NCT ID: NCT02220777 Org: User:
Start: 11/30/10 End: 05/31/11 Due: 05/31/12

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205

Phase: N/A Priority: Normal
NCT ID: NCT02314793 Org: User:
Start: 11/30/14 End: 10/31/15 Due: 10/31/16

A Study to Evaluate How Tamsulosin (at 1 Dose) and Solifenacin (at 2 Different Doses) Are Taken up From the Intestine, Distributed Through the Body and Eliminated From the Body When Administered in Combination as a Single Tablet (Called EC905)

Phase: N/A Priority: Normal
NCT ID: NCT01953848 Org: User:
Start: 04/30/10 End: 07/31/10 Due: 07/31/11

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01793077 Org: User:
Start: 12/31/11 End: 12/31/13 Due: 12/31/14

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

Phase: N/A Priority: Normal
NCT ID: NCT01911728 Org: User:
Start: 07/25/11 End: 02/21/12 Due: 02/21/13

A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178

Phase: N/A Priority: Normal
NCT ID: NCT01651312 Org: User:
Start: 01/31/03 End: 02/28/03 Due: 02/28/04

Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02072967 Org: User:
Start: 05/31/12 End: 10/31/15 Due: 10/31/16

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02169713 Org: User:
Start: 05/31/14 End: 08/31/14 Due: 08/31/15

A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02116582 Org: User:
Start: 05/23/14 End: 09/29/17 Due: 09/29/18

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02155504 Org: User:
Start: 05/31/14 End: 10/31/14 Due: 10/31/15

A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men

Phase: N/A Priority: Normal
NCT ID: NCT02138162 Org: User:
Start: 08/31/13 End: 03/31/14 Due: 03/31/15

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02136316 Org: User:
Start: 05/31/14 End: 11/30/15 Due: 11/30/16

A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01579461 Org: User:
Start: 11/30/08 End: 04/30/09 Due: 04/30/10

A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function

Phase: N/A Priority: Normal
NCT ID: NCT02161224 Org: User:
Start: 09/30/13 End: 12/31/13 Due: 12/31/14

To Determine the Feasibility of a Fidaxomicin Study in Neonates and to Assess C. Difficile (Clostridium Difficile) Involvement in the Pathogenesis

Phase: N/A Priority: Normal
NCT ID: NCT01533844 Org: User:
Start: 03/31/12 End: 09/30/14 Due: 09/30/15

A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01815684 Org: User:
Start: 08/31/12 End: 12/31/12 Due: 12/31/13

A Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02447315 Org: User:
Start: 05/31/15 End: 06/30/15 Due: 06/30/16

EC905 Pharmacokinetic Profile Study

Phase: N/A Priority: Normal
NCT ID: NCT02634489 Org: User:
Start: 03/31/09 End: 07/31/09 Due: 07/31/10

A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

Phase: N/A Priority: Normal
NCT ID: NCT02010944 Org: User:
Start: 09/30/12 End: 11/30/12 Due: 11/30/13

A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02124668 Org: User:
Start: 09/23/14 End: 05/25/17 Due: 05/25/18

A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin

Phase: N/A Priority: Normal
NCT ID: NCT01953887 Org: User:
Start: 03/31/10 End: 07/31/10 Due: 07/31/11

A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT02965040 Org: User:
Start: 12/12/16 End: 12/11/17 Due: 12/11/18

Absolute Bioavailability Study With Ipragliflozin

Phase: N/A Priority: Normal
NCT ID: NCT01611428 Org: User:
Start: 06/30/11 End: 07/31/11 Due: 07/31/12